Allogeneic HSCT · 10 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Etoposide and TBI Variant #01 | — | R 8 617 | — | — | — | — | — | — |
Busulfan and Cyclophosphamide Variant #01 | — | R 7 711 | — | — | — | — | — | — |
BEAM Variant #01 Partial | — | R 4 294 | — | — | — | — | — | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | — | — | 2 |
Fludarabine and TBI for haploidentical transplant, then allo HSCT N/A - secondary systemic drug | — | R 1 031 | — | — | — | — | — | — |
BFR Partial | — | — | — | — | — | — | — | — |
BuCyTBI Partial | — | — | — | — | — | — | — | — |
Busulfan and Fludarabine Partial | — | — | — | — | — | — | — | — |
Fludarabine, Busulfan, Cyclophosphamide Partial | — | — | — | — | — | — | — | — |
Busulfan, Cyclophosphamide, Decitabine, G-CSF Partial | — | — | — | — | — | — | — | — |
10 of 10 regimens shown